Drug intelligence / Profile preview

propofol + remifentanil + sufentanil

Development stage: Unknown
Lead developer: AkzoNobel
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of three anesthetic agents used for total intravenous anesthesia (TIVA). Propofol is a short-acting intravenous anesthetic agent, remifentanil is a potent short-acting synthetic opioid with rapid onset and recovery, and sufentanil is a powerful synthetic opioid approximately 5-10 times more potent than fentanyl. This combination provides effective sedation, analgesia, and anesthesia while potentially reducing the individual doses needed of each component, resulting in improved hemodynamic stability and reduced stress responses during surgical procedures.

Targets

GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on propofol + remifentanil + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + remifentanil + sufentanil.

Explore the full profile